Incyte Corporation

INCY

Healthcare Biotechnology

Incyte Corporation’s revenue for fiscal 2025 (year ended December 2025) was $5.1 billion, up 21.2% from fiscal 2024.

Revenue
+14.0%
EPS
−277.9%
Free cash flow
−233.0%
Total debt
−10.5%

Quarter to September 2026, against a year earlier

121.89 0.38 −0.31%
Market cap
$24.9B
P/E
58.1×
Fwd P/E
57.3×
Dividend yield
—
F-score
9/9
ROIC
21.6%
Net debt / EBITDA
−2.2×
Dividend safety
n/a
Older periods Dec '25 Mar '26 Jun '26 Sep '26
Piotroski F-Score

+8 more TTM periods

9 8 6 6
ROE
29.87% 30.82% 30.67% 7.84%
ROA
20.75% 21.88% 23.55% 5.92%
ROIC
58.55% 61.52% 60.50% 21.56%
Return on Tangible Assets
30.35% 30.37% 29.73% 8.43%
Average Days of Receivables
72.73 71.59 70.57 75.12
Free Cash Flow per Share
6.81 7.13 9.43 3.35
Free Cash Flow
1,329.63 1,420.88 1,890.47 679.87
Other line items

Show all line items

Columns are period end dates · fundamentals updated 2 Nov 2026